retatrutide news today recency 3 glp-1 GLP-1 trends 2025: real-world data, patient outcomes & future therapies Lilly's triple agonist, retatrutide, delivered

It represents a strategic evolution in therapeutic development, moving beyond single-target approaches to multi-receptor agonism

Verified customer Superb 10 months in and lost a considerable fraction of my initial weight absolutely worth it Vivian S

Increase in circulating GLP-1 following low FODMAP diet in irritable bowel syndrome patients

As a result, healthcare providers cannot routinely prescribe it as an FDA-approved medication

GLP-1 medications carry important warnings and contraindications, including a boxed warning for thyroid C-cell tumors in rodents (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)